Watchlist

Watchlist
Anthera Pharmaceuticals, Inc. (ANTH)
Anthera Pharmaceuticals, Inc. (ANTH)
ROTY Edition 1 Volume 70: A Solid Start To January And Thoughts On Taking Profits
Welcome to the 70th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril…
Omeros: Competition In IgAN, But OMS721 Has The Lead
Omeros Corporations ( OMER ) lead drug candidate is OMS721, which is going through trials in IgA Nephropathy. We have covered the stock extensively, and readers know we are bullish OMER. However, we would be remiss in our due diligence if we did not discuss some of the main competition…
ROTY Edition 1 Volume 69: BTD For Global Blood Therapeutics And Other Updates
Welcome to the 69th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril…
ROTY Edition 1 Volume 61: ASH Updates And Trades
Welcome to the 61st entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
Premarket Gainers as of 9:05 am
More news on: Blueprint Medicines, Catalyst Inc., bluebird bio, Inc., Stocks on the move, Read more …
ROTY Edition 1 Volume 59: Updates And Trades
Welcome to the 59th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
ROTY Edition 1 Volume 56: Cidara Therapeutics In The Spotlight
Welcome to the 56th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
Anthera Pharmaceuticals: Buy The Dip
Shares of Anthera Pharmaceuticals ( ANTH ) have fallen by 15% since I suggested that readers buy the stock in anticipation of a run-up into a data release in the first quarter of 2018. ANTH data by YCharts Today, I am revisiting to provide more thoughts on the potential here as well as re-…
ROTY Edition 1 Volume 55: Selecting Our 10th Position On A Pullback
Welcome to the 55th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar…
A Current Look At The ROTY Contenders List
ROTY (Runners of the Year) is a strategy which involves two parts, the official 10 stock model account and our Contenders List of ideas. Basically, we are looking for stocks that could outperform (ideally double or more) within the near to medium term (next quarter to 12 months out). While the…
Premarket Losers as of 9:05 am
CHFS -14% . More news on: CHF Solutions, Inc., Meridian Waste Solutions, Inc., Anthera Pharmaceuticals, Inc., Stocks on the move, Read more …
Anthera Pharmaceuticals, Inc. (ANTH)